Business
Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing
About this update from Veru Inc.
[{"type":"text","content":"MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that two of its abstracts have been accepted for presentation at the upcoming 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held February 13-15, 2020, at the Moscone West Building in San Francisco, California. \n One of the presentations will provide preclinical data on VERU-100, the Company’s novel, proprietary peptide formulation for androgen deprivation therapy (ADT) developed with multiple potential beneficial clinical attributes to address the shortfalls of current FDA-approved ADT formulations for the treatment of advanced prostate cancer. VERU-100 is a long-acting gonadotropin-releasing hormone (GnRH) antagonist designed to be administered as a small volume subcutaneous 3-month depot injection without a loading dose. The other presentation reports findings from a recent study in a contemporary cohort of men on ADT to determine the magnitude of the impact that hot flashes are having on these men and their disease management. The Company has a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist, Zuclomiphene citrate, that is currently being evaluated in a Phase 2 clinical study to treat hot flashes, one of the most common and impactful side effects caused by ADT. Additional information on the meeting can be found on the ASCO Genitourinary Cancers Symposium website: http://gucasym.org/. The full abstracts will be made available online via https://meetinglibrary.asco.org at 5:00 PM (EST) on February 10, 2020. Presentation details: Abstract Title: Determination of the ability of a novel, long-acting subcutaneous GnRH antagonist, VERU-100, to castrate without a testosterone surge in a rat modelPresenter: Robert H. Getzenberg, Ph.D.Abstract Number: 128 Board Number: F8 Session Information: Poster Session A: Prostate CancerDate/Time: 02/13/2020, 11:30 AM – 1:00 PM and 5:30 PM – 6:30 PMAbstract Title: Survey of ADT-induced estrogen deficiency-related side effects in a contemporary cohort of men with advanced prostate cancerPresenter: Robert H. Getzenberg, Ph.D.Abstract Number: 235Board Number: B13Session Information: Poster Session B: Prostate Cancer;...